UK-based pharmaceutical company Futura Medical (FUM) , has announced that it has been granted allowance of its EU patent which will provide protection for MED3000 until 2040 in all European markets.
MED3000 - Eroxon in Europe - is a topical, gel-based erectile dysfunction treatment.
In all other key markets including the US, Futura is continuing to prosecute patent applications to provide wider patent protection and further options for patent filings to extend scope of protection is also progressing.
James Barder, Chief Executive Officer of Futura said: "The allowance of this patent application further cements the intellectual property of MED3000, as we support our distributors' roll out of our fast acting topically applied gel for the treatment of erectile dysfunction available without a doctor's prescription across the world. This is an important next step as we continue to grow our business and strengthen the Eroxon® brand."
View from Vox
Futura being granted allowance of its EU patent means it can secure IP protection of MED3000 alongside confidently expanding its presence and distribution across European markets.
Futura has been making strides with MED3000 in Europe, with launches in Belgium and the UK exceeding expectations, indicating around 20% market share of clinically proven ED treatments.
Futura’s strategy to secure partners to launch and market its products is a winning formula for the company. In Europe, the company’s commercial partner Cooper Consumer Health - a leading over-the-counter drug manufacturer and distributor - has helped Futura’s Eroxon exceed sales expectations compared to its original first year forecasts.
Follow Futura Medical for more News and Updates: